EN DE
Data-driven stock valuation

Star Sports Medicine Co., Ltd. (1609) fair value: what the stock is really worth

We calculate from audited financials what Star Sports Medicine Co., Ltd. is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.

  1. Compare price with fair valuebelow fair value = cheap, above = expensive
  2. Check the quality50 and up solid, 75 and up strong
  3. Watch it or check another stockalert when fair value or trend changes

Healthcare · HK · Market cap HK$8.5B (≈ $1.1B)

At a glance

SS Star Sports Medicine Co., Ltd. 1609 · HK
PriceHK$112.70
Fair ValueHK$51.39
Upside−54.4%
Quality74/100

A solid business, but trading 119% above our fair value of HK$51.39.

As of Sep 3, 2026, the fair value of Star Sports Medicine Co., Ltd. is HK$51.39 per share against a price of HK$112.70, so the fair value sits 54% below the price. A model estimate from reported figures, not an analyst target.

✓Healthy Growth (revenue 3y +40.1 %/yr)
✓Highly profitable · 34.0% net margin
✓Low debt · generates free cash flow
!Mixed vs. peers (6/13)
✓Wide moat 72/100
!Evidence only medium, so the estimate is less certain
Evidence: Medium Range HK$39.06 to HK$63.71

Fair value as of: Sep 3, 2026

From 24 valuation models · updated 7 days ago

Fair value updated Sep 3, 2026, revised from HK$51.26 to HK$51.39 (+0.3%) since Aug 13, 2026. Share price −12.8% over the past month.

Watch Star Sports Medicine Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • A high-quality business (quality 74/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
  • The price sits above even our optimistic bull case (HK$63.71). The favourable scenario is already priced in.

Price vs Fair Value (4 months)

HK$218.40 HK$112.70 Fair Value HK$51.39 May 2026 Sep 2026

White line = price, green steps = our fair value per fiscal year. As of Sep 3, 2026.

How to read this chart

4‑month range HK$112.70 – HK$218.40 · fair‑value band HK$39.06 – HK$63.71 · the HK$112.70 price screens above the HK$51.39 fair value. As of Sep 3, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Star Sports Medicine Co., Ltd. (1609) currently trades at HK$112.70, while our model-based Fair Value estimate is HK$51.39, implying the stock looks roughly 119.3% overvalued today. The Quality Score stands at 74/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of HK$102.09 per share, and 1 of the 24 models we run sit above the HK$112.70 price. Bear case: the Asset-Based group reads lowest at HK$7.45, and 23 of the 24 models stay below the price. Evidence for this calculation is medium.

Over the trailing twelve months, Star Sports Medicine Co., Ltd. generated revenue of HK$403M at a net margin of 34.0%. It earns a return on equity of 25.4%. The stock trades on a trailing P/E of 53.8 (as of Jul 2, 2026). Fundamentals as of Sep 3, 2026

Scenario range: HK$39.06 (bear) to HK$63.71 (bull), the price of HK$112.70 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 62% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −31% fair-value upside, at −54%, 1609 screens richer than that median.

Fair Value models

Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF HK$37.43 HK$56.67 HK$116.64 73
Growth DCF HK$35.26 HK$65.51 HK$114.23 72
EPV HK$23.20 HK$26.58 HK$29.50 71
All 24 models by family
DCF Models
FCF DCF HK$37.43 HK$56.67 HK$116.64 73
Owner Earnings HK$33.63 HK$72.36 HK$150.67 68
5Y Revenue Exit HK$19.30 HK$28.59 HK$47.73 68
5Y EBITDA Exit HK$35.39 HK$61.12 HK$111.56 69
5Y P/E Exit HK$41.03 HK$90.34 HK$157.68 64
10Y Revenue Exit HK$24.63 HK$43.76 HK$53.40 64
10Y EBITDA Exit HK$36.51 HK$77.62 HK$148.82 61
10Y P/E Exit HK$40.53 HK$89.48 HK$170.22 57
Earnings-Based
Graham-Dodd HK$16.99 HK$118.46 HK$166.24 60
Lynch FV HK$53.16 HK$75.94 HK$98.72 58
PEG = 1.0 HK$53.16 HK$75.94 HK$98.72 55
EPV HK$23.20 HK$26.58 HK$29.50 71
Multiples
P/E Multiple HK$39.34 HK$52.46 HK$65.57 63
P/S Multiple HK$11.02 HK$14.69 HK$18.36 58
P/B Multiple HK$31.85 HK$42.47 HK$53.08 55
EV/EBIT HK$39.81 HK$52.48 HK$65.15 66
EV/EBITDA HK$33.50 HK$44.07 HK$54.64 67
EV/Revenue HK$11.04 HK$15.01 HK$18.98 54
Asset-Based
NCAV (Graham) HK$5.56 HK$7.45 HK$11.11 54
Growth DCF
Growth DCF HK$35.26 HK$65.51 HK$114.23 72
Rev-Margin DCF HK$20.33 HK$32.50 HK$57.02 67
Economic Profit
Residual Income HK$16.16 HK$21.66 HK$104.36 55
ROIC Compounder HK$30.72 HK$47.49 HK$60.76 68
Growth Earnings
Growth-Adj P/E HK$71.46 HK$102.09 HK$132.71 65

Widest divergence: Growth Earnings (HK$102.09) versus Asset-Based (HK$7.45). Highest evidence: FCF DCF (73).

Notify me when 1609 reaches fair value

Put 1609 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 53.8 as of Jul 2, 2026
P/S ratio 18.3 P/E × margin
Net margin 34.0% FY2025
Return on equity 25.4% TTM
Return on assets (EBIT) 15.3% avg 4y
Operating margin 7.5% TTM
More key figures
Growth
Revenue (TTM) HK$403M TTM
Balance sheet & cash flow
Free cash flow HK$123M FY2025

Figures from reported company fundamentals · as of Sep 3, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 74/100

Of which business quality 75 · Market factors (momentum, volatility) 0

Profitability 76
Margins and returns on capital today
Quality Growth 78
Are margins and returns improving?
Cashflow 79
Earnings quality: real cash, not paper profit
Fin. Strength 90
Balance sheet, leverage, solvency risk
Investment 21
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Star Sports Medicine Co., Ltd. manufactures and markets clinical products and solutions for sports medicine in China. The company offers medical implant, such as bioabsorbable suture anchor, includes all-suture anchor, PEEK suture anchor, and carbon fiber reinforced PEEK suture anchor; interference screws and sheath fixation system, bioabsorbable …

Full company description

Star Sports Medicine Co., Ltd. manufactures and markets clinical products and solutions for sports medicine in China. The company offers medical implant, such as bioabsorbable suture anchor, includes all-suture anchor, PEEK suture anchor, and carbon fiber reinforced PEEK suture anchor; interference screws and sheath fixation system, bioabsorbable interference screw, bioabsorbable interference screws and sheath fixation system, PEEK screws and sheath fixation system, and PEEK composite interference screw; suture buttons and high-strength sutures, such as adjustable suture button, fixed suture button, ultra-high molecular weight polyethylene(UHMWPE) suture; meniscus repair systems, all-suture meniscus repair system, accurFix all-inside meniscus repair system, and multi-needle and flexible meniscus repair system. The surgical equipment and associated medical consumables, includes plasma RF ablation equipment, arthroscopic surgical shaver, arthroscopic camera system, and disposable shaver blade plasma electrode. Its other products includes disposable PRP preparation kit, desktop centrifuge. The company also provides biomaterial platform, imaging and dynamic platform, intelligent medicine platform, and tissue engineering platform. The company was founded in 2017 and is headquartered in Beijing, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2025 · reported fiscal years

Star Sports Medicine Co., Ltd. reported revenue of 403M CNY in FY2025 versus 147M CNY in FY2022, a compound +40.1%/yr. Reported net income was 137M CNY in FY2025, compounding +50.3%/yr from FY2022.

Growth Quality 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
HK$403M
Latest YoY
+23.1%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+40.1%
Value creation/yr (3Y) ⓘEarnings growth per share (CAGR 3 years) plus dividend yield: value created per share and year.
≈ +41.1%
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share+41.1%
Dividend yield0.0%
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.23.8% (2022) → 40.6% (2025) · rising
⚠ Final year 2025 sits 140% above trend (one-off), rate approximate
Revenue +40.1%/yr
FY22 147M CNY
FY23 239M CNY
FY24 327M CNY
FY25 403M CNY
Net income +50.3%/yr
FY22 40.3M CNY
FY23 57.1M CNY
FY24 95.4M CNY
FY25 137M CNY

1609 screens 119% overvalued. Compare with Abbott Laboratories, →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Star Sports Medicine Co., Ltd. · Fair Value
HK$51.39 −119%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Star Sports Medicine Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/1609

Peer Group

Medical Devices · 353 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation
Quality Score 74 · Top 25%
Fair Value upside −63% · Bottom 25%
Profitability
Return on equity (TTM) 25% · Top 25%
Return on assets 12% · Top 25%
Net margin (TTM) 34% · Top 25%
Operating margin (TTM) 8% · Above median
Growth and dividend
Revenue growth 0% · Below median
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiples vs Medical Devices median · lower = cheaper

P/E (TTM) 53.8× · Priciest 25%
P/B 13.95× · Priciest 25%
P/S (TTM) 21.10× · Priciest 25%
P/FCF 8.8× · Pricier than median
EV/EBITDA 58.6× · Priciest 25%

What the price implies (reverse DCF)

The inverse question: what free-cash-flow growth must Star Sports Medicine Co., Ltd. deliver for ten years so that today's price is fair in our DCF model? Same formula, same discount rate as the fair value.

Implied FCF growth, 10 years+24.5 % per year
Achieved revenue growth, 3 years+40.1 % p.a.
Sector median revenue growth+4.6 %
FCF yield on price1.99 %
Discount rate (WACC) in the models11.8 %

The price demands less growth than the company recently delivered: even a weaker business would justify the price. Ranking of the largest stocks →

Context: sector, industry, market

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 0
FUTURE0 · sector 32
PAST100 · sector 3
HEALTH98 · sector 97
DIVIDEND0 · sector 35

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Sep 3, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $108.33 $74.79 −31%
Stryker Corporation SYK $303.13 $186.28 −39%
Medtronic plc MDT $94.17 $65.57 −30%
Boston Scientific Corporation BSX $47.80 $30.73 −36%
Edwards Lifesciences Corporation EW $89.78 $41.02 −54%
Siemens Healthineers AG SHL €39.00 €33.87 −13%
DexCom, Inc DXCM $87.90 $38.95 −56%
GE HealthCare Technologies Inc GEHC $74.82 $64.13 −14%
Koninklijke Philips N.V PHIA €23.69 €14.36 −39%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥150.63 ¥147.63 −2%

Compare Star Sports Medicine Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Frequently asked questions

Is Star Sports Medicine Co., Ltd. (1609) overvalued or undervalued?
As of Sep 3, 2026, our model estimates a fair value of HK$51.39 versus a price of HK$112.70, about −54% upside (overvalued).
What is the fair value of 1609?
Our model-based fair value for Star Sports Medicine Co., Ltd. is HK$51.39 (as of Sep 3, 2026), built from audited fundamentals. The current price: HK$112.70.
What is the quality score of 1609?
Star Sports Medicine Co., Ltd. has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Star Sports Medicine Co., Ltd. (1609)?
Our model-based price target is the fair value of HK$51.39 (as of Sep 3, 2026) from 24 valuation models. Cautious scenario HK$39.06, optimistic scenario HK$63.71. It is a calculation from audited fundamentals, not an analyst target.
What is the Star Sports Medicine Co., Ltd. stock forecast for 2026?
Our models put fair value at HK$51.39, about −54% upside versus a price of HK$112.70 (overvalued). Cautious scenario HK$39.06, optimistic scenario HK$63.71. The calculation is refreshed regularly with new filings.
What is the revenue of Star Sports Medicine Co., Ltd. (1609)?
Star Sports Medicine Co., Ltd. reported trailing-twelve-month revenue of about HK$403M (latest available figure, as of Sep 3, 2026).
What is the net profit margin of 1609?
The net profit margin of Star Sports Medicine Co., Ltd. is about 34.0%, meaning it keeps roughly 34.0% of revenue as net income. Based on the latest reported figures.
What growth is priced into Star Sports Medicine Co., Ltd. (1609)?
For today's price to be fair in a discounted-cash-flow model, Star Sports Medicine Co., Ltd. would have to grow free cash flow by +24.5 % per year for ten years (discount rate 11.8 %, then 2 % perpetual growth). Over the last 3 years revenue grew +40.1 % per year. As of Sep 3, 2026.
What discount rate (WACC) does the fair value of 1609 use?
Our models discount Star Sports Medicine Co., Ltd. at 11.8 %: a base by market capitalisation (small), country premium for Hong Kong. The same rate applies in all 26 models.
What is the intrinsic value of Star Sports Medicine Co., Ltd. (1609)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Star Sports Medicine Co., Ltd. it is HK$51.39 per share (as of Sep 3, 2026), against a price of HK$112.70. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Star Sports Medicine Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 3, 2026, 1609 trades above its calculated fair value: price HK$112.70, fair value HK$51.39, a gap of about −54% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1609?
No. The price is what the market pays today (HK$112.70); the fair value is what the company's own numbers justify (HK$51.39). For Star Sports Medicine Co., Ltd. the two are HK$61.31 per share apart. That gap is exactly why we show both numbers side by side.
How much is Star Sports Medicine Co., Ltd. worth?
The market values Star Sports Medicine Co., Ltd. at about HK$8.5B (market capitalisation, as of Sep 3, 2026). Per share that is HK$112.70; our models calculate a fair value of HK$51.39 per share.
What do the bullish and bearish scenarios say about 1609?
Our models span a range for Star Sports Medicine Co., Ltd.: cautious scenario HK$39.06, base HK$51.39, optimistic HK$63.71 per share (as of Sep 3, 2026, price HK$112.70). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1609?
Star Sports Medicine Co., Ltd. trades at a price-to-earnings ratio of 53.8 (as of Sep 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$51.39 is built from several models across several years. Other multiples: P/B 14.0, P/S 21.1, EV/EBITDA 58.6.
How solid is the balance sheet of Star Sports Medicine Co., Ltd. (1609)?
Balance-sheet figures for Star Sports Medicine Co., Ltd. (as of Sep 3, 2026): return on equity 25.4%, debt of 0.03 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is 1609 from its 52-week high?
Star Sports Medicine Co., Ltd. trades at HK$112.70, about 62% below its 52-week high of HK$299.00 (as of Sep 3, 2026). Distance from the high says nothing about value: that is what the fair value of HK$51.39 is for.
Which stocks are comparable to Star Sports Medicine Co., Ltd.?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Star Sports Medicine Co., Ltd. stock attractive at the current price?
The data as of Sep 3, 2026: price HK$112.70, calculated fair value HK$51.39 (−54%), Quality Score 74/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1609 calculated?
We run Star Sports Medicine Co., Ltd. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$51.39, with the spread shown as a cautious and an optimistic scenario.
Free · no account needed

Watch Star Sports Medicine Co., Ltd. in the live analysis

One click puts Star Sports Medicine Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.